MX2018009008A - Virus atenuados de bronquitis infecciosa. - Google Patents

Virus atenuados de bronquitis infecciosa.

Info

Publication number
MX2018009008A
MX2018009008A MX2018009008A MX2018009008A MX2018009008A MX 2018009008 A MX2018009008 A MX 2018009008A MX 2018009008 A MX2018009008 A MX 2018009008A MX 2018009008 A MX2018009008 A MX 2018009008A MX 2018009008 A MX2018009008 A MX 2018009008A
Authority
MX
Mexico
Prior art keywords
infectious bronchitis
bronchitis virus
attenuated infectious
attenuated
coronavirus
Prior art date
Application number
MX2018009008A
Other languages
English (en)
Inventor
Bickerton Erica
Keep Sarah
Britton Paul
Original Assignee
The Pirbright Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Pirbright Inst filed Critical The Pirbright Inst
Publication of MX2018009008A publication Critical patent/MX2018009008A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Abstract

La presente invención proporciona un coronavirus atenuado vivo que comprende una mutación en la proteína estructural nsp-3 y/o eliminación de proteínas accesorias 3a y 3b. El coronavirus se puede usar como una vacuna para tratar y/o prevenir una enfermedad, tal como bronquitis infecciosa, en un paciente.
MX2018009008A 2016-01-27 2017-01-26 Virus atenuados de bronquitis infecciosa. MX2018009008A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1601498.7A GB201601498D0 (en) 2016-01-27 2016-01-27 Coronavirus
PCT/GB2017/050192 WO2017129975A1 (en) 2016-01-27 2017-01-26 Attenuated infectious bronchitis virus

Publications (1)

Publication Number Publication Date
MX2018009008A true MX2018009008A (es) 2018-11-19

Family

ID=55535017

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009008A MX2018009008A (es) 2016-01-27 2017-01-26 Virus atenuados de bronquitis infecciosa.

Country Status (17)

Country Link
US (1) US11202825B2 (es)
EP (1) EP3408381B1 (es)
JP (1) JP2019503693A (es)
KR (1) KR20180104088A (es)
CN (1) CN108884447B (es)
AU (1) AU2017211507B2 (es)
BR (1) BR112018015453A2 (es)
CA (1) CA3012024A1 (es)
CL (1) CL2018001946A1 (es)
GB (1) GB201601498D0 (es)
IL (1) IL259655A (es)
MX (1) MX2018009008A (es)
PE (1) PE20190121A1 (es)
PH (1) PH12018501154A1 (es)
RU (1) RU2018130683A (es)
WO (1) WO2017129975A1 (es)
ZA (1) ZA201803700B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110592031B (zh) * 2019-09-25 2023-03-14 华南农业大学 一株S蛋白融合HiBiT的传染性支气管炎重组病毒及制备方法与应用
CN111437384A (zh) * 2020-04-07 2020-07-24 四川骋誉生物制品有限公司 用于预防covid-19的蝙蝠源性冠状病毒疫苗
BR102020019867A2 (pt) * 2020-09-28 2022-04-12 Fundacao Univ Estadual Do Ceara Funece Uso da vacina de coronavírus aviário (ibv) como modelo de imunização em mamíferos contra sars-cov 2
JP2024004496A (ja) * 2020-10-14 2024-01-17 一般財団法人阪大微生物病研究会 ノックアウトコロナウイルス
CN113308440B (zh) * 2021-05-26 2023-04-28 武汉大学 一种n7-甲基转移酶缺陷型冠状病毒减毒疫苗株及其制备方法与应用
CN114807061A (zh) * 2021-12-22 2022-07-29 华南农业大学 鸡传染性支气管炎标记疫苗毒株及其制备方法、疫苗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037650A (en) 1988-03-08 1991-08-06 Akzo N.V. Live combination vaccine
NZ507793A (en) 1998-05-01 2003-05-30 Schering Plough Ltd Recombinant virus expressing foreign DNA encoding feline CD80, feline CTLA-4 or feline CD86 and uses thereof
PL207933B1 (pl) * 2001-05-17 2011-02-28 Stichting Tech Wetenschapp Wyizolowana lub zrekombinowana replikatywna cząsteczka podobna do koronawirusa, kompozycja zawierająca tą cząsteczkę do zastosowania terapeutycznego, do zastosowania jako immunogen lub szczepionka i do zastosowania diagnostycznego
DE602004023594D1 (de) 2003-03-03 2009-11-26 Inst Animal Health Newbury Ein virus der infektiösen bronchitis mit veränderten spike-gen
RU2253870C1 (ru) 2004-04-26 2005-06-10 Общество с ограниченной ответственностью Научно-производственное объединение "Диагностические системы" РЕКОМБИНАНТНЫЕ БЕЛКИ, СОДЕРЖАЩИЕ ДИАГНОСТИЧЕСКИ ЗНАЧИМЫЕ АНТИГЕННЫЕ ЭПИТОПЫ БЕЛКОВ КОРОНАВИРУСА (SARS-CoV), СВЯЗАННОГО С ТЯЖЕЛЫМ ОСТРЫМ РЕСПИРАТОРНЫМ СИНДРОМОМ, И ПОСЛЕДОВАТЕЛЬНОСТИ СИНТЕТИЧЕСКИХ ГЕНОВ, КОДИРУЮЩИХ ДИАГНОСТИЧЕСКИ ЗНАЧИМЫЕ АНТИГЕННЫЕ ДЕТЕРМИНАНТЫ БЕЛКОВ КОРОНАВИРУСА (SARS-CoV), СВЯЗАННОГО С ТЯЖЕЛЫМ ОСТРЫМ РЕСПИРАТОРНЫМ СИНДРОМОМ
KR100902510B1 (ko) * 2007-08-27 2009-06-15 삼성전자주식회사 한 개의 스위칭 소자와 한 개의 저항체를 포함하는비휘발성 메모리 장치
GB0911794D0 (en) 2009-07-07 2009-08-19 Animal Health Inst Chimaeric protein

Also Published As

Publication number Publication date
WO2017129975A1 (en) 2017-08-03
GB201601498D0 (en) 2016-03-09
CA3012024A1 (en) 2017-08-03
IL259655A (en) 2018-07-31
PH12018501154A1 (en) 2019-01-28
KR20180104088A (ko) 2018-09-19
RU2018130683A3 (es) 2020-04-21
RU2018130683A (ru) 2020-02-27
CN108884447B (zh) 2022-07-26
AU2017211507A1 (en) 2018-06-28
JP2019503693A (ja) 2019-02-14
CN108884447A (zh) 2018-11-23
PE20190121A1 (es) 2019-01-17
BR112018015453A2 (pt) 2018-12-18
EP3408381A1 (en) 2018-12-05
AU2017211507B2 (en) 2022-09-29
CL2018001946A1 (es) 2019-02-15
ZA201803700B (en) 2022-12-21
US20190022214A1 (en) 2019-01-24
EP3408381B1 (en) 2021-06-23
US11202825B2 (en) 2021-12-21

Similar Documents

Publication Publication Date Title
PH12018501154A1 (en) Attenuated infectious bronchitis virus
MX2016016722A (es) Coronavirus.
PH12019502003A1 (en) Cyclic sulfamide compounds and methods of using same
MX2018014573A (es) Vacuna contra el virus del zika.
EA201890527A1 (ru) Терапевтические вакцины против hpv18
PH12020500080A1 (en) Senecavirus a immunogenic compositions and methods thereof
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
PH12015502790A1 (en) Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof
MX370079B (es) Vacuna profilactica contra el sindrome de caida del huevo (eds).
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
PH12016502002A1 (en) Novel bacteriophage and composition comprising same
MX2017002803A (es) Coronavirus bovino atenuado y vacunas relacionadas.
PH12017500450A1 (en) Flavivirus virus like particle
MX2018006416A (es) Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina.
MX2019005102A (es) Poxvirus quimericos sinteticos.
MX2018005462A (es) Composiciones inmunogénicas de rsv quimérico y métodos de uso.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MX2018016306A (es) Virus de enteritis de pato y usos del mismo.
PH12017500088A1 (en) Antagonists of neurokinin b in fish reproduction
UA122339C2 (uk) Вірус качиного ентериту та його застосування
EA201891555A1 (ru) Вирус вакцины от репродуктивно-респираторного синдрома свиней
PH12016502000B1 (en) Novel bacteriophage and composition comprising same
NZ728041A (en) Substances and methods for the use in prevention and/or treatment in huntington’s disease
MX2017009796A (es) Mdv1 recombinantes y usos de los mismos.
BR112017004008A2 (pt) polipeptídeo recombinante, sequência de ácido nucleico, célula hospedeira, bionanopartícula, métodos para produção de uma bionanopartícula e para tratamento ou prevenção do vírus da dengue, e, vacina.